Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | CCNE2 | O96020 | 2/20 | 0.43 |
| ▸ | CDK4 | P11802 | 2/20 | 0.43 |
| ▸ | CCND1 | P24385 | 2/20 | 0.43 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.43 |
| ▸ | CDK2 | P24941 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.42 |
| ▸ | PRKACA | P17612 | 1/20 | 0.42 |
| ▸ | PRKACG | P22612 | 1/20 | 0.42 |
| ▸ | PRKACB | P22694 | 1/20 | 0.42 |
| ▸ | BRD9 | Q9H8M2 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | TAF1 | P21675 | 1/20 | 0.42 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.42 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.42 |
| ▸ | CECR2 | Q9BXF3 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29809554 | 1.00 | MEN1 (0.49) | MEN1KMT2ACCNE2CDK4CCND1 | |
| SCHEMBL31378640 | 0.85 | CYP2A6 (0.42) | MEN1KMT2ACCNE2CDK4CCND1 | |
| SCHEMBL349421 | 0.85 | CYP2A6 (0.42) | MEN1KMT2ACCNE2CDK4CCND1 | |
| SCHEMBL12177181 | 0.81 | BRD9 (0.42) | MEN1KMT2ACDK2BRD9LMNA | |
| SCHEMBL25927403 | 0.79 | KMT2A (0.44) | MEN1KMT2ACCNE2CDK4CCND1 | |
| SCHEMBL23346719 | 0.79 | PRKCI (0.56) | CDK2BRD9BRD4TAF1BRPF1 | |
| SCHEMBL9919031 | 0.79 | BRD9 (0.41) | BRD9BRD4TAF1BRPF1CREBBP | |
| SCHEMBL31743100 | 0.79 | BRD9 (0.41) | BRD9BRD4TAF1BRPF1CREBBP | |
| SCHEMBL29809118 | 0.79 | CCNE2 (0.41) | CCNE2CDK4CCND1CCNE1CDK2 | |
| SCHEMBL582859 | 0.79 | CCNE2 (0.41) | CCNE2CDK4CCND1CCNE1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210147364-A1 | A CATALYST BOUND ALPHA RADICAL AND SYNTHESIS OF OXO COMPOUNDS USING THE SAME | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2021-05-20 | — | — | US | claimed |
| EP-4134364-B1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2025-07-30 | — | — | EP | disclosed |
| US-20240182490-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2024-06-06 | — | — | US | disclosed |
| US-11884680-B2 | Bromodomain inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2024-01-30 | — | — | US | disclosed |
| US-11834689-B2 | Incorporation of unnatural nucleotides and methods thereof | THE SCRIPPS RESEARCH INSTITUTE (US) | 2023-12-05 | — | — | US | disclosed |
| EP-4265608-A1 | BENZOHETEROCYCLE SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUND | Shanghai Jemincare Pharmaceuticals Co., Ltd. (CN) | 2023-10-25 | — | — | EP | disclosed |
| EP-4134364-A2 | BROMODOMAIN INHIBITORS | Celgene Quanticel Research, Inc. (US) | 2023-02-15 | — | — | EP | disclosed |
| EP-4134364-A2 | BROMODOMAIN INHIBITORS | Celgene Quanticel Research, Inc. (US) | 2023-02-15 | — | — | EP | disclosed |
| US-20220315601-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2022-10-06 | — | — | US | disclosed |
| EP-3640241-B1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2022-09-28 | — | — | EP | disclosed |
| EP-1651642-B1 | PNA MONOMER AND PRECURSOR | PANAGENE INC (KR) | 2009-11-04 | — | — | EP | disclosed |
| EP-1470114-B1 | PEPTIDE NUCLEIC ACID OLIGOMERS FROM 1-BENZENESULFONYL-3-AMINO ACID SIDE CHAIN-4-(2-NUCLEOBASE(ACETYL))-PIPERAZIN-2-ONES | PANAGENE INC (KR) | 2009-08-19 | — | — | EP | disclosed |
| US-20090087922-A1 | SINGLE NUCLEOTIDE POLYMORPHISM ANALYSIS OF HIGHLY POLYMORPHIC TARGET SEQUENCES | EPOCH BIOSCIENCES, INC. (US) | 2009-04-02 | — | — | US | disclosed |
| US-7411065-B2 | Peptide nucleic acid monomers: diphenylmethyl, benzyl, alkylthioalkyl, or phenylthioalkyl esters of N-(1-[4-(2-benzothiazolyl-, 2-benzoxazolyl-, 2-benzofuranyl- or 2-benzothiophenyl-sulfonyl)-3-piperazinon-1-ylcarbonylmethyl]pyrimidon-4-yl)carbamic acids | PANAGENE, INC. (KR) | 2008-08-12 | — | — | US | disclosed |
| US-7371860-B2 | PNA monomer and precursor | PANAGENE, INC. (KR) | 2008-05-13 | — | — | US | disclosed |
| US-7371859-B2 | Peptide nucleic acid monomers; 1-(4-(benzothiazolyl-, benzoxazolyl-, benzofuranyl-, and benzothiophenyl- sulfonyl)piperidin-3-one-1-ylcarbonylmethyl)adenines; suitable for automatic and parallel synthesis; increased yields | PANAGENE, INC. (KR) | 2008-05-13 | — | — | US | disclosed |
| US-7348146-B2 | Single nucleotide polymorphism analysis of highly polymorphic target sequences | EPOCH BIOSCIENCES, INC. (US) | 2008-03-25 | — | — | US | disclosed |
| US-20070105803-A1 | Methods and compositions for treating neurological disease | MASSACHUSETTS, UNIVERSITY OF | 2007-05-10 | — | — | US | disclosed |
| US-7211668-B2 | PNA monomer and precursor | PANAGENE, INC. (KR) | 2007-05-01 | — | — | US | disclosed |
| US-7179896-B2 | Method of making PNA oligomers | PANAGENE, INC. (KR) | 2007-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240182490-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | MEN1 3343/4885KMT2A 77/4885CCNE2 1952/4885 |
| US-20220315601-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | MEN1 3343/4885KMT2A 77/4885CCNE2 1952/4885 |
| US-20070105803-A1 | Methods and compositions for treating neurological disease | SMN1; SMN2, CLN6, INA | MEN1 1598/4885KMT2A 1675/4885CCNE2 4813/4885 |
| US-20210147364-A1 | A CATALYST BOUND ALPHA RADICAL AND SYNTHESIS OF OXO COMPOUNDS USING THE SAME | CBR1, POR, CAT | MEN1 892/4885KMT2A 2513/4885CCNE2 379/4885 |
| US-11884680-B2 | Bromodomain inhibitors | BRD3, EP300, BRPF3 | MEN1 3343/4885KMT2A 77/4885CCNE2 1952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.